



Information on the compensation of corporate officers

(in application of articles L. 22-10-8, L. 22-10-9, R. 22-10-14 and R. 22-10-15 of the French Commercial Code)

The combined general meeting of MaaT Pharma (the “**Company**”) which was held on May 28, 2024 at 10 a.m. at the registered office of the Company located 70 avenue Tony Garnier – 69007 Lyon, approved the resolution relating to the compensation policy for corporate officers in respect of the 2024 financial year (*Say on Pay ex-ante*), as well as the resolution relating to the information mentioned in I. of article L. 22-10-9 of the French Commercial Code (*Code de commerce*) relating to the compensation paid and/or granted to corporate officers in respect of the financial year ending December 31, 2023 (so-called “global” *Say on Pay ex-post*).

Pursuant to the provisions of articles L. 22-10-8, L. 22-10-9, R. 22-10-14 and R. 22-10-15 of the French Commercial Code, this information is presented below, supplemented for information purposes by the results of the votes on the resolutions relating to the individual compensation paid and/or allocated to the Company's corporate officers in respect of the financial year ending December 31, 2023 (so-called “individual” *Say on Pay ex-post*).

Resolution	Description	Results of the votes	Corresponding section in the 2022 Universal Registration Document (URD)
FOURTEENTH RESOLUTION	Approval of the information relating to the remuneration of corporate officers for the year 2022 mentioned in I of Article L. 22-10-9 of the French Commercial Code	Approved by 99,986 %	Universal Registration Document (Section 13 of the URD); Paragraph 13.2 (Ratio)
FIFTEENTH RESOLUTION	Approval of the elements of compensation paid during or allocated by way of the	Approved by 98,769 %	Universal Registration Document (Section 13 of the URD); Paragraph 13.1.1.1

	financial year 2023 to the Chairman of the Board of Directors		<i>(Corporate officers Compensation - Chairman of the Board of Directors)</i>
SIXTEENTH RESOLUTION	Approval of the elements of compensation paid during or allocated by way of the financial year 2023 to the Chief Executive Officer	Approved by 98,215 %	Universal Registration Document (Section 13 of the URD); Paragraph 13.1.1.2 <i>(Corporate officers Compensation - CEO)</i>
SEVENTEENTH RESOLUTION	Approval of the remuneration policy applicable for 2024 to the Chairman of the Board of Directors	Approved by 98,769 %	Universal Registration Document (Section 13 of the URD); Paragraph 13.1.1.1 <i>(Corporate officers Compensation - Chairman of the Board of Directors)</i>
EIGHTEENTH RESOLUTION	Approval of the remuneration policy applicable for 2024 to the Chief Executive Officer	Approved by 98,216 %	Universal Registration Document (Section 13 of the URD); Paragraph 13.1.1.2 <i>(Corporate officers Compensation - CEO)</i>
NINETEENTH RESOLUTION	Approval of the remuneration policy applicable for 2024 to directors	Approved by 98,761 %	Universal Registration Document (Section 13 of the URD); Paragraph 13.1.2 <i>(Directors compensation)</i>

* * *

About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company's Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).



Contacts

MaaT Pharma - Investor Relations

Guillaume DEBROAS, Ph.D.
Head of Investor Relations
+33 6 16 48 92 50
invest@maat-pharma.com

MaaT Pharma - Media Relations

Pauline RICHAUD
Senior PR & Corporate Communications Manager
+33 6 14 06 45 92
media@maat-pharma.com

Trophic Communications

Jacob VERGHESE or
Desmond JAMES
+49 151 7441 6179
maat@trophic.eu